Can reactive donor screening results be presumed false positive following unstandardized testing procedures?
Vox Sanguinis · 2023
DOI: 10.1111/vox.13490 ↗Kurz gefasst
Leserbrief in der Zeitschrift Vox Sanguinis, 2023. Verfasst von Ramune Sepetiene und 7 weiteren Autor:innen. Beteiligte Einrichtung: Abbott GmbH Max-Planck-Ring 2, Wiesbaden, Germany. Hauptthemen laut MEDLINE: Donor Selection, Blood Donors. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Abbott GmbH Max-Planck-Ring 2, Wiesbaden, Germany.
- Abbott srl, Rome, Italy.
- Abbott Laboratories, Duo Tower, Singapore.
- Abbott Laboratories GmbH, DAFZA, Dubai, United Arab Emirates.
- Abbott Laboratories, Bogotá D.C., Colombia.
- Abbott Laboratories, Chicago, Illinois, USA.
ORCID-Profile: Ramune Sepetiene, Guillermo Orjuela
Zitieren
APA
Sepetiene, R., Galli, C., Bhatnagar, S., Ali, M., Orjuela, G., Olson, E., Robbins, N., & Kang, J. (2023). Can reactive donor screening results be presumed false positive following unstandardized testing procedures?. Vox Sanguinis. https://doi.org/10.1111/vox.13490
Vancouver
Sepetiene R, Galli C, Bhatnagar S, Ali M, Orjuela G, Olson E, et al. Can reactive donor screening results be presumed false positive following unstandardized testing procedures?. Vox Sanguinis. 2023. doi:10.1111/vox.13490
BibTeX
@article{Sepetiene2023,
author = {Sepetiene, Ramune and Galli, Claudio and Bhatnagar, Sonu and Ali, Mohamed and Orjuela, Guillermo and Olson, Ellen and Robbins, Ninette and Kang, Jason},
title = {Can reactive donor screening results be presumed false positive following unstandardized testing procedures?},
journal = {Vox Sanguinis},
year = {2023},
doi = {10.1111/vox.13490}
}
EUVIMED